AKT1 and breast carcinoma: The compound has been shown to have the potential for therapeutic applications by inhibiting migration, invasion, and epithelial–mesenchymal transition (EMT) of breast cancer cells through the suppression of the Wnt/β-catenin and PI3K/AKT signaling pathways and by reducing PD-L1 expression [177].